Financial reports
20-F
2023 FY
Annual report (foreign)
1 Apr 24
20-F
2022 FY
Annual report (foreign)
1 May 23
20-F
2021 FY
Annual report (foreign)
28 Apr 22
20-F
2020 FY
Annual report (foreign)
30 Mar 21
20-F
2019 FY
Annual report (foreign)
15 Jun 20
20-F
2018 FY
Annual report (foreign)
15 May 19
NT 20-F
Notice of late annual filing (foreign)
1 May 19
20-F
2017 FY
Annual report (foreign)
30 Apr 18
20-F
2016 FY
Annual report (foreign)
1 May 17
Current reports
6-K
Agreement and Plan of Merger
11 Apr 24
6-K
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27 Mar 24
6-K
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
15 Mar 24
6-K
Report of Foreign Private Issuer
13 Mar 24
6-K
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
8 Mar 24
6-K
Report of Foreign Private Issuer
29 Feb 24
6-K
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
27 Feb 24
6-K
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
20 Feb 24
6-K
Report of Foreign Private Issuer
12 Feb 24
6-K
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
29 Jan 24
Registration and prospectus
425
Business combination disclosure
12 Apr 24
S-8
Registration of securities for employees
1 Apr 24
F-1
Registration statement (foreign)
27 Feb 24
8-A12B
Registration of securities on exchange
28 Nov 23
F-3/A
Shelf registration (foreign) (amended)
20 Nov 23
F-3
Shelf registration (foreign)
3 Nov 23
D
$5.03 mm in options, sold $5.03 mm, 1 investor
19 Oct 23
424B5
Prospectus supplement for primary offering
14 Aug 23
424B3
Prospectus supplement
10 Aug 23
424B3
Prospectus supplement
9 Aug 23
Proxies
No filings
Other
EFFECT
Notice of effectiveness
7 Mar 24
UPLOAD
Letter from SEC
18 Jan 24
CORRESP
Correspondence with SEC
5 Jan 24
UPLOAD
Letter from SEC
21 Dec 23
EFFECT
Notice of effectiveness
24 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
EFFECT
Notice of effectiveness
16 Mar 23
EFFECT
Notice of effectiveness
24 Feb 23
CORRESP
Correspondence with SEC
21 Feb 23
UPLOAD
Letter from SEC
21 Feb 23
Ownership
SC 13G
YA II PN, Ltd.
6 Mar 24
144
Notice of proposed sale of securities
21 Aug 23
SC 13G
Clearmind Medicine Inc.
13 Dec 22
SC 13G/A
EIDE ROBERT J
9 May 22
SC 13G/A
BIGGER CAPITAL FUND L P
11 Feb 22
SC 13G/A
BIGGER CAPITAL FUND L P
1 Feb 21
SC 13G
EIDE ROBERT J
9 Dec 20
SC 13D/A
L.I.A. Pure Capital Ltd
3 Dec 20
SC 13G
BIGGER CAPITAL FUND L P
30 Nov 20
SC 13G/A
MORGAN STANLEY
10 Aug 20